Korean biotech company liable in gene therapy dispute

A Korean biotech company has been ordered to pay US$40 million in an ICC arbitration over the mislabelling of a gene therapy treatment, a matter that caused a scandal in Korea and led to the prosecution of executives.


Get unlimited access to all Global Arbitration Review content